2016-09-02 18:14:30 UTC

Janssen to Provide Free Therapeutic Drug Monitoring for IBD Patients on Remicade

Sept. 2, 2016

You can leverage this program to evaluate how a patient is responding to Remicade and identify steps to optimize the patient’s response.

Janssen Biotech, Inc., has partnered with Miraca Life Sciences and its InformTx therapeutic drug monitoring service to develop the Janssen 2Inform program, which will provide two free therapeutic drug monitoring tests per year for patients with inflammatory bowel disease being treated with Remicade.

Through the program, therapeutic drug monitoring blood tests will be drawn from a patient and sent overnight to be analyzed by Miraca Life Sciences, which will then report results electronically to the physician within three-to-five business days. You can use these results to evaluate how a patient is responding to Remicade and, in turn, identify steps to optimize the patient’s response.

More information is available in this Healio Gastroenterology article.

More on IBD

2018 AGA Postgraduate Course

June 2, 2018

Secure your spot for this clinically focused, multi-topic course that offers immediately applicable information. Held in conjunction with DDW®. Save $75 when you register by April 18.

Advancing Collaborative Approaches in IBD Treatment Decision-Making

March 14, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.

Advancing Collaborative Approaches in IBD Treatment Decision-Making

March 12, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.